Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
Abstract
Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether this will impact on the clinical utility of CDK8/19 inhibitors. We discovered two series of potent chemical probes with high selectivity for CDK8/19. Despite pharmacodynamic evidence for robust on-target activity, the compounds exhibited modest, though significant, efficacy against human tumor lines and patient-derived xenografts. Altered gene expression was consistent with CDK8/19 inhibition, including profiles associated with super-enhancers, immune and inflammatory responses and stem cell function. In a mouse model expressing oncogenic beta-catenin, treatment shifted cells within hyperplastic intestinal crypts from a stem cell to a transit amplifying phenotype. In two species, neither probe was tolerated at therapeutically-relevant exposures. The complex nature of the toxicity observed with two structurally-differentiated chemical series is consistent with on-target effects posing significant challenges to the clinical development of CDK8/19 inhibitors.
Data availability
-
Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinasesPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE80472).
-
Effect of cortistatin A (CA) on enhancer occupancy in CA-sensitive and -insensitive human cell linesPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE65138).
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
-
Molecular Signatures Database v5.1Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.
Article and author information
Author details
Funding
Cancer Research UK (C309/A11566, C368/A6743, A368/A7990)
- Paul Workman
Breast Cancer Now (2008MayPR16)
- Trevor C Dale
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: In the UK, all animal work was conducted in accordance with National Institute for Cancer Research guidelines, with the research programme and procedures approved by the local Animal Welfare and Ethical Review Boards and subject to UK Government Home Office regulations (Licence PPL 70/7635 & PPL 30/3279). In Germany the animal work was carried out in accordance with the German Law on the Protection of Animals (Article 8a) and the pertaining files at the at the local animal welfare authorities in Darmstadt and Freiburg bear the references DA/375, DA4/1003, DA4/1004 and G13/13 respectively. The studies were designed in accordance with presently valid international study guidelines (e.g. ICH guideline M3 R2) and performed in compliance with animal health and welfare guidelines.The Institute of Cancer Research does not use non-rodent species in research and, where this is deemed essential, requires ethical approval for use by organizations with whom we collaborate. Pharmacokinetic and tolerability analysis of compounds in dogs, necessary for prediction of human pharmacokinetics, was approved by the ICR Animal Welfare and Ethical Review Board. Studies were sponsored and conducted in full compliance with national regulations at an Association for Assessment and Accreditation of Laboratory Animal Care accredited site of Merck Biopharma.
Copyright
© 2016, Clarke et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,284
- views
-
- 1,205
- downloads
-
- 72
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
Hepatocellular carcinoma (HCC), the most common type of liver tumor, is a leading cause of cancer-related deaths, and the incidence of liver cancer is still increasing worldwide. Curative hepatectomy or liver transplantation is only indicated for a small population of patients with early-stage HCC. However, most patients with HCC are not candidates for radical resection due to disease progression, leading to the choice of the conventional tyrosine kinase inhibitor drug sorafenib as first-line treatment. In the past few years, immunotherapy, mainly immune checkpoint inhibitors (ICIs), has revolutionized the clinical strategy for HCC. Combination therapy with ICIs has proven more effective than sorafenib, and clinical trials have been conducted to apply these therapies to patients. Despite significant progress in immunotherapy, the molecular mechanisms behind it remain unclear, and immune resistance is often challenging to overcome. Several studies have pointed out that the complex intercellular communication network in the immune microenvironment of HCC regulates tumor escape and drug resistance to immune response. This underscores the urgent need to analyze the immune microenvironment of HCC. This review describes the immunosuppressive cell populations in the immune microenvironment of HCC, as well as the related clinical trials, aiming to provide insights for the next generation of precision immunotherapy.
-
- Cancer Biology
- Genetics and Genomics
It takes more than 20 years for normal colorectal mucosa to develop into metastatic carcinoma. The long time window provides a golden opportunity for early detection to terminate the malignant progression. Here, we aim to enable liquid biopsy of T1a stage colorectal cancer (CRC) and precancerous advanced adenoma (AA) by profiling circulating small extracellular vesicle (sEV)-derived RNAs. We exhibited a full RNA landscape for the circulating sEVs isolated from 60 participants. A total of 58,333 annotated RNAs were detected from plasma sEVs, among which 1,615 and 888 sEV-RNAs were found differentially expressed in plasma from T1a stage CRC and AA compared to normal controls (NC). Then we further categorized these sEV-RNAs into six modules by a weighted gene coexpression network analysis and constructed a 60-gene t-SNE model consisting of the top 10 RNAs of each module that could well distinguish T1a stage CRC/AA from NC samples. Some sEV-RNAs were also identified as indicators of specific endoscopic and morphological features of different colorectal lesions. The top-ranked biomarkers were further verified by RT-qPCR, proving that these candidate sEV-RNAs successfully identified T1a stage CRC/AA from NC in another cohort of 124 participants. Finally, we adopted different algorithms to improve the performance of RT-qPCR-based models and successfully constructed an optimized classifier with 79.3% specificity and 99.0% sensitivity. In conclusion, circulating sEVs of T1a stage CRC and AA patients have distinct RNA profiles, which successfully enable the detection of both T1a stage CRC and AA via liquid biopsy.